Европейский союз - английский - EMA (European Medicines Agency)

laboratorios hipra, s.a. - recombinant verotoxin 2e of e. coli - inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) escherichia + clostridium, immunologicals for suidae - pigs - active immunisation of piglets from 2 days of age to prevent mortality and reduce clinical signs of oedema disease (caused by verotoxin 2e produced by e. coli) and to reduce the loss of daily weight gain during the finishing period in the face of infections with verotoxin 2e producing e. coli until slaughter from 164 days of age.

Европейский союз - английский - EMA (European Medicines Agency)

laboratorios hipra, s.a. - lipoteichoic acid from biofilm adhesion component of streptococcus uberis, strain 5616 - immunologicals for bovidae - cattle - for active immunisation of healthy cows and heifers to reduce the incidence of clinical intramammary infections caused by streptococcus uberis, to reduce the somatic cell count in streptococcus uberis positive quarter milk samples and to reduce milk production losses caused by streptococcus uberis intramammary infections.

Европейский союз - английский - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - pigs - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies).to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies.to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies).mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

Европейский союз - английский - EMA (European Medicines Agency)

laboratorios hipra, s.a. - clostridioides difficile toxoid a, clostridioides difficile toxoid b, clostridium perfringens, type a, alpha toxoid - immunologicals for suidae, inactivated bacterial vaccines for pigs, clostridium - pigs - for the passive immunisation of neonatal piglets by means of the active immunisation of breeding sows and gilts:- to prevent mortality and reduce clinical signs and macroscopic lesions caused by clostridioides difficile toxins a and b.- to reduce clinical signs and macroscopic lesions caused by clostridium perfringens type a, alpha toxin.

Европейский союз - английский - EMA (European Medicines Agency)

laboratorios hipra, s.a. - erysipelothrix rhusiopathiae, strain r32e11 (inactivated) - immunologicals for suidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) escherichia + clostridium - pigs - for the active immunisation of male and female pigs to reduce clinical signs (skin lesions and fever) of swine erysipelas caused by erysipelothrix rhusiopathiae, serotype 1 and serotype 2.

Европейский союз - английский - EMA (European Medicines Agency)

laboratorios hipra, s.a. - porcine parvovirus, strain nadl-2 and erysipelothrix rhusiopathiae, strain r32e11 (inactivated) - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - pigs - for the active immunisation of female pigs for the protection of progeny against transplacental infection caused by porcine parvovirus.for the active immunisation of male and female pigs to reduce clinical signs (skin lesions and fever) of swine erysipelas caused by erysipelothrix rhusiopathiae, serotype 1 and serotype 2.

Европейский союз - английский - EMA (European Medicines Agency)

laboratorios hipra s.a. - live attenuated bovine respiratory syncytial virus (brsv), strain lym-56 - immunologicals for bovidae, cattle, live viral vaccines, bovine respiratory syncytial virus (brsv) - cattle - active immunisation of cattle to reduce virus shedding and respiratory clinical signs caused by bovine respiratory syncytial virus infection.

Нидерланды - английский - HMA (Heads of Medicines Agencies)

laboratorios hipra s. a. - live infectious bursal disease virus, strain ch/80 3.5 log10 ccid50, live infectious bursal disease virus, strain ch/80 5.5 log10 ccid50 - oral lyophilisate - chicken broilers - avian infectious bursal disease virus (gumboro disease)

Австрия - английский - HMA (Heads of Medicines Agencies)

laboratorios hipra s. a. - live infectious bursal disease virus, strain ch/80 3.5 log10 ccid50, live infectious bursal disease virus, strain ch/80 5.5 log10 ccid50 - oral lyophilisate - chicken broilers - avian infectious bursal disease virus (gumboro disease)

Германия - английский - HMA (Heads of Medicines Agencies)

laboratorios hipra s. a. - live infectious bursal disease virus, strain ch/80 3.5 log10 ccid50, live infectious bursal disease virus, strain ch/80 5.5 log10 ccid50 - oral lyophilisate - chicken broilers - avian infectious bursal disease virus (gumboro disease)